Skip to main content
. Author manuscript; available in PMC: 2023 Jun 26.
Published in final edited form as: Arthritis Care Res (Hoboken). 2023 Jan 4;75(3):449–464. doi: 10.1002/acr.25045

Table 3.

Medication management at the time of non–live attenuated vaccine administration

Influenza vaccination Other non–live attenuated vaccinations
Methotrexate Hold methotrexate for 2 weeks after vaccination* Continue methotrexate
Rituximab Continue rituximab Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination
Immunosuppressive medications other than methotrexate and rituximab Continue immunosuppressive medication Continue immunosuppressive medication

Inline graphic = Conditional recommendation.

*

Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patients rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.

Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.